Common prognostic factors do not fully predict clinical outcomes in colorectal cancer, one of the most common malignancies in developed countries. Therefore, biological prognostic markers are under investigation. We investigated the prognostic value of expression of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-2 and TIMP-3) in rectal carcinoma to predict survival of the patients. Retrospective analysis of clinicopathological findings of 64 patients who underwent rectal resection due to carcinoma and were followed-up from 2 to 96 months (median 48) was performed. Semi-quantitative scoring was used to assess the expression levels of MMP-2, MMP-9, TIMP-2 and TIMP-3 in rectal carcinoma. During the follow-up, 28 patients died. The deceased patients demonstrated significantly higher expression of MMP-9 and lower expression of TIMP-3 in parenchyma of carcinoma and lower expression of TIMP-2 in stroma of carcinoma, compared to survivors. Moreover, the deceased patients were associated with advanced tumor, metastases in lymph nodes and distant metastases. According to univariate analysis longer survival was predicted by lower expression of MMP-9 in parenchymal cells ( p = 0.03), tumor size (early tumor) ( p = 0.026), absence of metastases in lymph nodes ( p = 0.02) or distant metastases ( p = 0.04). Multivariate analysis revealed that metastases in lymph nodes, higher expression of MMP-9 in parenchyma, and lower expression of MMP-9 in stromal cells significantly increased mortality. Expression of MMP-9 in rectal carcinoma is a prognostic marker for overall survival. It is important to identify the origin of MMP-9 to predict better overall survival of the patients.
One of the most common types of cancer is colorectal cancer, which is distinguished for its increased morbidity. In developed countries, colorectal cancer is the third most common type of cancer after lung and prostate cancer in men and breast and skin cancer in women. Based on the data presented by Cancer Registry, Lithuania is in a similar situation; in the year 2007, 39 in 100,000 men and 36 in 100,000 women were diagnosed with colorectal cancer. Rectal cancer comprised nearly half of these cases, whereas colon cancer comprised one fourth of them. Improvement in surgery techniques and extension of the possibilities of conservative treatment have led to an increase of five-year survival rate now amounting to 40% (Weitz et al. 2005) .
It is proved that survival and prognosis of the disease depend on the stage of tumor, its differentiation grade, and completeness of its resection. These indices are the basis for planning the treatment and prognosis of the course of the disease. However, a clinical course of tumor, even diagnosed at the same stage, may vary substantially. Such findings challenge to search for new prognostic markers and to study processes taking place in the tissue of a malignant tumor.
In the course of progression of malignant tumor, proteases destroy basal membranes and extracellular connective tissue (ECT). Matrix metalloproteinases (MMPs) present a large family of Zn and Ca ions-dependent proteases that destroy intercellular matrix both under physiological conditions and pathological conditions of the remodelling processes. Analysis of the gene sequence and proteins encoded by genes has allowed to define a complete set of MMPs produced by human cells; there have been identified 24 different genes encoding proteases of the MMP family (Puente et al. 2003) . They participate in many processes taking place in the organism starting with embryogenesis (Vu and Werb 2000; Zhou et al. 2000) . During investigations of tumors, great attention is paid to gelatinases MMP-2 and MMP-9, both of which destroy type IV collagen, one of the main components of ECT and basement membrane. The predominant opinion is that the role of gelatinases is essential in invasion of malignant tumor and development of metastases (Yoon et al. 2003) .
To maintain balance, MMPs tissue inhibitors (TIMPs), which suppress proteolysis, are produced in the tissues. These are specific substances produced by the cells and binding to MMPs in the ratio 1:1. Currently, four TIMPs suppressing all known MMPs are detected in mammalian organisms (Visse and Nagase 2003) . Both malignant tumor cells and healthy cells constantly secrete MMPs and TIMPs. However, secretion of MMPs tends to be more active in malignant tumor tissues. The effect of TIMPs is multiple and is not restricted only to MMPs inhibition (Coussens et al. 2002) . TIMP-2 and TIMP-3 have wider ranges of biological activities independent of MMP inhibition. Only TIMP-2 interacts with pro-MMP-2, and consequently, pro-MMP-2 is activated. TIMP-2 has erythroid potentiating, cell growth promoting and antiangiogenetic effects by binding to α 3 β 1 integrin (Seo et al. 2003) . TIMP-3 inhibits a broad array of metalloproteinases as well as members of a disintegrin and metalloprotease (ADAM), and a disintegrin a n d m e t a l l o p r o t e a s e w i t h t r o m b o s p o n d i n m o t i f s (ADAMTS) (Wang et al. 2006) ; as a result, it reduces inflammatory reaction and growth of cancer cells. TIMP-3 induces apoptosis of cancer and vascular cells and regulates angiogenesis (Rundhaug 2005; Brew and Nagase 2010) . Thus, the purpose of our study is to investigate the prognostic value of expression profiles of MMP-2 and MMP-9 and their inhibitors TIMP-2 and TIMP-3 in rectal carcinoma to predict survival of patients who undergo surgery.
Material and Methods
After approval by Kaunas Regional Ethics Committee for Biomedical Research (Protocol No. 134/2006) , the data of patients who underwent radical rectal resection for adenocarcinoma in 2000-2003 at the Department of Surgery of Kaunas University of Medicine Hospital were analyzed retrospectively. All patients had rectal adenocarcinomas confirmed by histopathology and were staged according to the 5th edition of the American Joint Committee on Cancer (AJCC) Staging Manual (Fleming 1997) . Patients underwent radical low anterior or abdominoperineal rectum resection with total mesorectal excision. The exclusion criteria were a synchronous tumor or tumor in another location in anamnesis, radiation treatment or emergency surgery. Study included 64 patients. The following clinical characteristics were evaluated: age, gender, TNM stage, histological differentiation of the tumor according to the data of histopathological investigation, and the patient follow-up information (overall survival) ( Table 1 ). The mean age of the patients was 70.14 ± 9.42 (ranging from 45 to 87 years of age). They were followed up from 2 to 96 months (median of 48 months). During the follow up 28 patients died. pT1 and pT2 tumor were grouped together as T E (early tumor), whereas pT3 and pT4 tumor were pooled in group T A (advanced tumor). pN1 and pN2 were combined to N M (lymph node metastases). For the purposes of description of tumor differentiation, G1 and G2 were pooled in group G G (tumor of good differentiation), whereas G3 and G4 were grouped together as G P (tumor of poor differentiation).
Immunohistochemistry
Paraffin-embedded blocks of resected tumor tissue were taken from the archives of the Department of Pathological Anatomy, Kaunas University of Medicine. Paraffin-embedded specimens were sectioned in 3 μm slices and mounted on "SuperFrost Plus" glass slides. Before staining the glass slides were left in a thermostat at a temperature of 37ºC overnight and at a temperature of 58ºC for 3 hours. Deparaffinization was performed with the automatic slide stainer Varistain Gemini (ThermoShandon Ltd, UK), with the help of xylene and ethanol. Then, sections were washed with distilled water and heated in TRIS/EDTA buffer (pH 9.0) for 8 minutes at 110°C using a microwave histoprocessor RHS-1 (Milestone S.r.l, Italy) for epitope retrieval. Immunohistochemistry was performed with the help of the Shandon Coverplate system. After blocking endogenous peroxidase activity, all slides were incubated with the primary antibody for MMP-2 (clone 17B11, Novocastra Laboratories Ltd., UK) and MMP-9 (clone 15W2, Novocastra Laboratories Ltd., UK) at a dilution of 1:50, TIMP-2 (clone 46E5, Novocastra Laboratories Ltd., UK) at a dilution of 1:200 and TIMP-3 (clone 18D12b, Novocastra Laboratories Ltd., UK) at a dilution of 1:50 for 1 hour in Antibody Diluent (Dako Denmark A/S) and then processed using the peroxidase-based EnVision™ visualization system for MMP-9 (Dako Denmark A/S) and ADVANCE™ (Dako Denmark A/S) kit for MMP-2, TIMP-2 and TIMP-3. Finally, the sections were counterstained with Mayer's hematoxylin and mounted using xylene-based mounting medium. Dead 28
Evaluation of expression of matrix metalloproteinases and their tissue inhibitors
Two independent observers, who did not know the clinical data of the patients, semi-quantitatively evaluated the expression of MMP-2 and MMP-9 ( Fig. 1 A and B) and that of TIMP-2 and TIMP-3 ( Fig. 2 C and D ) in parenchymal and stromal cells of the tumor from 0 (no expression) to 3 (maximal expression) points and the amount of positively stained cells (0 -no stained cells, 1 -up to 10% stained cells, 2 -from 10 to 50% stained cells, and 3 -more than 50% stained cells) (Lipponen and Collan 1992) . In cases when evaluation of the observers differed by more than one point, the specimens were evaluated repeatedly. The intensity of protein expression in parenchymal and stromal cells was calculated by multiplying the estimated protein expression score by the amount of stained cells. The scores estimated by both observers were summed. Thus, the final score of the protein expression in parenchymal and stromal cells ranged from 0 to 18.
Statistical analysis
For statistical analysis, SPSS 15.0 for Windows (SPSS Inc., Chicago, IL) was used. The Student's t-test for independent samples was used to compare differences of means. Non-parametric data were compared using the Kruskall-Wallis test. The critical scores of markers were detected using the Kaplan-Meier method. The significance of survival differences was calculated for each possible critical value, and the value of the critical score matching the highest level of statistical significance was picked. Univariate analysis of survival was estimated by the Kaplan-Meier method and compared using the log rank test. Multivariate analysis was performed using Cox proportional hazard model involving all markers under investigation with p < 0.3 obtained during survival analysis using the log rank test. p ≤ 0.05 was considered statistically significant.
Results

Overall survival according to the clinical characteristics and expression profiles of MMPs and TIMPs
Comparison of clinical characteristics of survivors and dead patients during the follow up is presented in Table 2 . Significantly greater number of patients with advanced tumor, lymph nodes metastases and distant metastases was in the group of the dead patients as compared to the survivor group. Data about expression of MMPs and TIMPs in the groups of survivors and dead patients are presented in Table 3 . Expression of MMP-9 was significantly higher and expression of TIMP-3 was significantly lower in parenchyma of the carcinoma tissue from the patients who died during the follow up as compared to those who survived. Expression of TIMP-2 in stroma cells of carcinoma tissue was significantly lower in dead patients group as compared to the survivors.
Univariate analysis of survival
Significance of expression of MMPs, TIMPs and of clinical parameters for overall survival was detected by univariate analysis (Table 4) . It showed that significantly longer survival was predicted by expression of MMP-9 in parenchyma of carcinoma scoring lower than 9 points ( p = 0.03), tumor size T E ( p = 0.026), absence of lymph node metastases ( p = 0.02) and absence of distant metastases ( p = 0.04). Survival curves according to Kaplan-Meier are shown in Fig. 2 . 
Multivariate analysis of survival
Multivariate analysis revealed the following markers that significantly increased the risk of mortality in patients treated with surgery due to rectal adenocarcinoma (Table 5): • Metastases in regional lymph nodes 6 times increase the risk of mortality ( p = 0.018) ;
• Expression of MMP-9 in parenchyma of carcinoma scoring higher than 9 points almost 20 times increases the risk of mortality ( p = 0.001);
• Expression of MMP-9 in stroma of carcinoma scoring lower than 8 points 9 times increases the risk of mortality ( p = 0.003).
Discussion
The present study investigated prognostic value of the expression of MMP-2, MMP-9, TIMP-2 and TIMP-3 in parenchyma and stroma of rectal carcinoma to predict overall survival of the patients treated with surgery only. Most of the studies have established a relationship between the intensity of MMPs expression and clinical characteristics of malignant tumor such as the tumor invasion, state of lymph nodes, distant metastases and differentiation grade (Waas et al. 2002; Hilska et al. 2007 ). TIMPs are the substances that suppress MMP activities, thus regulating tissue remodelling. The lack of TIMPs in tumor tissues is known to result in more active remodelling of ECT, invasion of malignant tumor, and increase in metastatic tendency (Baker and Leaper 2003) . Studies investigating prognostic value of molecular markers have demonstrated that higher expression of TIMP-3 is related to more favourable clinical criteria and suggests better prognosis for malignant tumor. We also found that patients who died during follow up had statistically significantly lower expression of TIMP-3 in parenchyma and TIMP-2 in stroma cells of the tumor as compared to survivors as well as less favorable clinical criteria, i.e significantly higher prevalence of advanced tumor, metastases in lymph nodes or distant ones. Such protective effects of TIMP-3 and TIMP-2 in malignant tumor is thought to be determined by direct MMPs inhibition as well (pN1 and pN2) ; G G , tumor of good differentiation (G1 and G2); G P , tumor of poor differentiation (G3 and G4). as by TIMP-3 ability to suppress angiogenesis and stimulate apoptosis of malignant cells (Hilska et al. 2007) . A considerable amount of studies has been conducted to examine significance of gelatinases, i.e MMP-2 and MMP-9 in prognostication of malignant potential of tumor and related mortality rate. Unfortunately, the data often are controversial. According to some authors, though higher expression of gelatinases is not related to the tumor stage, it reflects higher invasive potential of tumor (Mook et al. 2004 ). One of the largest studies in this field with 212 patients has established that expression of gelatinases is not a prognostic marker for survival (Ring et al. 1997) . Some researchers cannot find a statistically significant relationship between higher expression of MMP-9 and shorter overall survival (Waas et al. 2002; Moran et al. 2005 ). In contrast, other studies have shown that higher expression of MMP-9 is a marker of poorer prognosis . According to our data, expression of MMP-9 in parenchyma of carcinoma tissue in patients who died during the follow up was significantly higher than in the samples from survivors. It can be stated that higher expression of MMP-9 in parenchyma of carcinoma tissue led to higher metastatic potential of malignant tumor, and distant metastases are the main cause of death from rectal carcinoma (Islekel et al. 2007) . Univariate and multivariate analysis of survival proved prognostic significance of expression of MMP-9 in carcinoma tissue as well. So according to the univariate analysis, survival is predicted by such clinical characteristics as low tumor invasion (T1-T2), absence of metastasis in regional lymph nodes (N0), absence of distance metastases (M0), and expression of MMP-9 in parenchymal cells less than 9 scores. Moreover, according to the multivariate analysis, expression of MMP-9 in parenchyma and stroma of carcinoma tissue has different impact on the risk of mor- *, value of the critical score on the basis of which survival probability is calculated. T E , early tumor (pT1 and pT2); T A , advanced tumor (pT3 and pT4); N M, lymph node metastases (pN1 and pN2); G G, tumor of good differentiation (G1 and G2); G P , tumor of poor differentiation (G3 and G4).
tality. Expression of MMP-9 in parenchyma of carcinoma scored higher than 9 points and its expression in stroma scored lower than 8 points significantly increased the risk of mortality. A strong relation was demonstrated between over-expression of MMP-9 in epithelial cells of colorectal cancer and locoregional metastases (Zuzga et al. 2008 ).
According to these data, Zuzga et al. (2008) concluded that the over-expression of MMP-9 in pure tumor epithelial (but nor stromal) cell population was associated with metastatic progression of colorectal cancer. Previous studies demonstrated that MMP-9 is expressed mostly by such stroma cells as fibroblasts, neutrophils, and macrophages (Zeng T A , advanced tumor (pT3 and pT4); N M , lymph node metastases (pN1 and pN2); G P , tumor of poor differentiation (G3 and G4).
and Guillem 1996; Nielsen et al. 1996) . It is suggested that the stromal reaction to tumor formation may represent a potentially protective anti-tumor host-defense mechanism (Lubbe et al. 2006 ). This idea is supported by our data. Indeed, lower expression of MMP-9 in the stroma was one of the criteria to worsen survival prognosis. In order to verify the MMP-9 positive stromal cells, we used anti-CD68 monoclonal antibody (marker for macrophages). The macrophages amounted a great part of stromal cells of the tumor (data are not shown). Lubbe et al. (2006) stated importance to identify the source of MMP-9 secretion in the tumor. According to them, general MMP-directed therapies that are otherwise untargeted with respect to the source of enzyme, may abrogate those critical adaptive antitumor mechanisms (Lubbe et al. 2006 ). Thus our data support hypothesis that MMP-9 expression in parenchyma and stroma cells of carcinoma tissue reflects different pathological processes in development of malignant tumor.
In conclusion, expression of MMP-9 in rectal carcinoma tissue is a strong prognostic marker for overall survival in patients who underwent surgery. It is important to identify the source of this enzyme in order to predict better overall survival of the patients, as higher expression of MMP-9 in parenchyma of carcinoma and its lower expression in stroma significantly increase the risk of mortality.
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